The new INNOVANCE® PFA P2Y cartridge is sensitive to the detection of the P2Y12 receptor inhibition

Platelets

Volumn 22, Issue 1, 2011, Pages 19-25

  Koessler, Juergen ^a   Kobsar, Anna L ^a   Rajkovic, Mirjana S ^a,b   Schafer, Andreas ^a   Flierl, Ulrike ^a   Pfoertsch, Stephanie ^a   Bauersachs, Johann ^a   Steigerwald, Udo ^a   Rechner, Andreas R ^c   Walter, Ulrich ^a  

^a UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^b UNIVERSITY MEDICINE GREIFSWALD   (Germany)

^c Siemens Healthcare Diagnostics Products GmbH   (Germany)

Author keywords

antiplatelet therapy; cangrelor; clopidogrel; INNOVANCE PFA P2Y*; platelet reactivity index (PRI); VASP

Indexed keywords

ACETYLSALICYLIC ACID; CANGRELOR; CLOPIDOGREL; PHOSPHOPROTEIN; PURINERGIC P2Y12 RECEPTOR; ACTIN BINDING PROTEIN; ADENOSINE PHOSPHATE; ANTITHROMBOCYTIC AGENT; BIOLOGICAL MARKER; CELL ADHESION MOLECULE; DRUG DERIVATIVE; PURINERGIC P2 RECEPTOR; PURINERGIC P2 RECEPTOR ANTAGONIST; TICLOPIDINE; VASODILATOR STIMULATED PHOSPHOPROTEIN; VASODILATOR-STIMULATED PHOSPHOPROTEIN;

ADULT; AGED; ANTICOAGULATION; ARTICLE; ASSAY; COMPARATIVE STUDY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DEVICE; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; HUMAN; HUMAN TISSUE; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SENSITIVITY AND SPECIFICITY; TREATMENT RESPONSE; BIOASSAY; BLOOD; CASE CONTROL STUDY; CORONARY ARTERY DISEASE; DRUG EFFECT; FLOW CYTOMETRY; METABOLISM; MIDDLE AGED; PHOSPHORYLATION; PREDICTIVE VALUE; THROMBOCYTE;

ADENOSINE MONOPHOSPHATE; ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL ASSAY; BIOLOGICAL MARKERS; BLOOD PLATELETS; CASE-CONTROL STUDIES; CELL ADHESION MOLECULES; CORONARY ARTERY DISEASE; FEMALE; FLOW CYTOMETRY; HUMANS; MALE; MICROFILAMENT PROTEINS; MIDDLE AGED; PHOSPHOPROTEINS; PHOSPHORYLATION; PLATELET AGGREGATION INHIBITORS; PREDICTIVE VALUE OF TESTS; PURINERGIC P2 RECEPTOR ANTAGONISTS; RECEPTORS, PURINERGIC P2; SENSITIVITY AND SPECIFICITY; TICLOPIDINE; YOUNG ADULT;

EID: 78651478309     PISSN: 09537104     EISSN: 13691635     Source Type: Journal    
DOI: 10.3109/09537104.2010.514967     Document Type: Article

References (13)

1. Sweeny JM, Gorog DA, Fuster V. Antiplatelet drug resistance. Part 1: Mechanisms and clinical measurements. Nat Rev Cardiol 2009;6:273-282.
2. Barragan P, Bouvier JL, Roquebert PO, Macaluso G, Commeau P, Comet B, Lafont A, Camoin L, Walter U, Eigenthaler M. Resistance to thienopyridines: Clinical detection of coronary stent thrombosis by monitoring of vasodilator- stimulated phosphoprotein phosphorylation. Catheter Cardiovasc Interv 2003;59:295-302.
3. Geiger J, Brich J, Honig-Liedl P, Eigenthaler M, Schanzenbacher P, Herbert JM, Walter U. Specific impairment of human platelet P2Y(AC) ADP receptor-mediated signaling by the antiplatelet drug clopidogrel. Arterioscler Thromb Vasc Biol 1999;19:2007-2011.
4. Michelson AD. P2Y12 antagonism: Promises and challenges. Arterioscler Thromb Vasc Biol 2008;28:s33-38.
5. Cattaneo M. Resistance to antiplatelet drugs: Molecular mechanisms and laboratory detection. J Thromb Haemost 2007;5(Suppl 1):230-237.
6. Blindt R, Stellbrink K, de Taeye A, Muller R, Kiefer P, Yagmur E, Weber C, Kelm M, Hoffmann R. The significance of vasodilator-stimulated phosphoprotein for risk stratification of stent thrombosis. Thromb Haemost 2007;98:1329-1334.
7. Bonello L, Paganelli F, Arpin-Bornet M, Auquier P, Sampol J, Dignat-George F, Barragan P, Camoin-Jau L. Vasodilatorstimulated phosphoprotein phosphorylation analysis prior to percutaneous coronary intervention for exclusion of postprocedural major adverse cardiovascular events. J Thromb Haemost 2007;5:1630-1636.
8. Frere C, Cuisset T, Quilici J, Camoin L, Carvajal J, Morange PE, Lambert M, Juhan-Vague I, Bonnet JL, Alessi MC. ADP-induced platelet aggregation and platelet reactivity index VASP are good predictive markers for clinical outcomes in non-ST elevation acute coronary syndrome. Thromb Haemost 2007;98:838-843.
9. Bonello L, Camoin-Jau L, Arques S, Boyer C, Panagides D, Wittenberg O, Simeoni MC, Barragan P, Dignat-George F, Paganelli F. Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: A multicenter randomized prospective study. J Am Coll Cardiol 2008;51:1404-1411.
10. Geiger J, Teichmann L, Grossmann R, Aktas B, Steigerwald U, Walter U, Schinzel R. Monitoring of clopidogrel action: Comparison of methods. Clin Chem 2005;51:957-965.
11. Aleil B, Ravanat C, Cazenave JP, Rochoux G, Heitz A, Gachet C. Flow cytometric analysis of intraplatelet VASP phosphorylation for the detection of clopidogrel resistance in patients with ischemic cardiovascular diseases. J Thromb Haemost 2005;3:85-92.
12. Rechner AR, Oehler C, Zander NF. Sensitive detection of the inhibition of the platelet P2Y12-receptor using the PFA-100- system with a new cartridge. Poster, 52 nd Meeting of the Gesellschaft fuer Thrombose und Haemostaseforschung, Wiesbaden, 2008: abstract P-14-08.
13. Schafer A, Weinberger S, Flierl U, Eigenthaler M, Stork S, Walter U, Ertl G, Bauersachs J. ADP-induced platelet aggregation frequently fails to detect impaired clopidogrel-responsiveness in patients with coronary artery disease compared to a P2Y12-specific assay. Thromb Haemost 2008;100:618-625.